Paragon Genomics
PrivateLast Round
Series A
Sep 12, 2017
Total Funding Raised
$8M
Company Overview
Paragon Genomics operates in Healthcare & Life Sciences and is based in Fremont, California. Its latest recorded funding round was a Series A round in September 2017.
Paragon Genomics is a life science company that develops and commercializes advanced target enrichment and library preparation solutions for Next-Generation Sequencing (NGS).
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Biotech Equipment, Precision Medicine
Business Model
B2B
Customer Profile
Hardware Sales, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Paragon Genomics Comparables
Compare Paragon Genomics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Pillar Biosciences | 86% | |
| SeqWell | 85% | |
| Pillar Therapeutics, Inc. | 84% |
For institutional investors. Book with your work email.
Paragon Genomics Funding Rounds
Historical fundraising activity
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Paragon Genomics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Heda Ventures | Series A |
| Cloudstone Capital | Series A |
| HEDA Ventures | Series A |
| Cowin Capital | Series A |
| Wisemont Capital | Series A |
Recent news
Latest coverage and updates
- integrates_withNov 10, 2026
On Nov 10th '26, Paragon Genomics agrees to integrate its CleanPlex PGx assay into Intelliseq's iFlow Platform and GeneSpect PGx Reporter for automated secondary bioinformatics analysis and comprehensive pharmacogenomics reporting.
For institutional investors. Book with your work email.
Paragon Genomics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Paragon Genomics's valuation, stock price, and market status.
Is Paragon Genomics a public or private company?
Paragon Genomics is a private company.
What is the current stock price of Paragon Genomics?
Paragon Genomics is a private company, so its shares have no public market price. Caplight tracks Paragon Genomics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Paragon Genomics worth (valuation)?
Valuation information for Paragon Genomics is not publicly available.
Can I buy Paragon Genomics stock?
Paragon Genomics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Paragon Genomics's last funding round?
Paragon Genomics's most recent funding round was Series A on September 12, 2017.
Who are the main investors in Paragon Genomics?
Key investors in Paragon Genomics include Cowin Capital.
Will Paragon Genomics IPO soon?
No public IPO plans have been announced for Paragon Genomics.
How can I track Paragon Genomics secondary market activity?
Caplight tracks bids, offers, and trades in Paragon Genomics's shares on secondary markets.